Technical Analysis for VYNT - Vyant Bio, Inc.

Grade Last Price % Change Price Change
F 3.65 0.27% 0.01
VYNT closed up 0.27 percent on Friday, April 16, 2021, on 23 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical VYNT trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup 0.27%
Narrow Range Bar Range Contraction 0.27%
NR7 Range Contraction 0.27%
NR7-2 Range Contraction 0.27%
Wide Bands Range Expansion 0.27%
Oversold Stochastic Weakness 0.27%
Slingshot Bearish Bearish Swing Setup -4.95%
Older End-of-Day Signals for VYNT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 1 day ago
Up 2% 1 day ago
Up 1% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vyant Bio, Inc. Description

Vyant Bio, Inc. (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Life Sciences Pharmaceutical Industry Health Sciences Medication Drug Discovery Stem Cells Clinical Research Drug Development Software Technologies Investigational New Drug

Is VYNT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.5
52 Week Low 2.11
Average Volume 2,319,145
200-Day Moving Average 3.92
50-Day Moving Average 5.45
20-Day Moving Average 4.65
10-Day Moving Average 3.99
Average True Range 0.56
ADX 18.82
+DI 24.51
-DI 26.28
Chandelier Exit (Long, 3 ATRs ) 5.80
Chandelier Exit (Short, 3 ATRs ) 5.15
Upper Bollinger Band 6.39
Lower Bollinger Band 2.91
Percent B (%b) 0.21
BandWidth 74.75
MACD Line -0.53
MACD Signal Line -0.42
MACD Histogram -0.102
Fundamentals Value
Market Cap 14.87 Million
Num Shares 4.07 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -7.09
Price-to-Sales 0.84
Price-to-Book 2.07
PEG Ratio -0.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.02
Resistance 3 (R3) 4.00 3.86 3.96
Resistance 2 (R2) 3.86 3.76 3.87 3.94
Resistance 1 (R1) 3.75 3.71 3.81 3.77 3.92
Pivot Point 3.61 3.61 3.64 3.62 3.61
Support 1 (S1) 3.51 3.52 3.56 3.53 3.38
Support 2 (S2) 3.37 3.46 3.38 3.36
Support 3 (S3) 3.26 3.37 3.34
Support 4 (S4) 3.28